The Effect of HIV-1 Resistance Mutations after First-Line Virological Failure on the Possibility to Sequence Antiretroviral Drugs in Second-Line Regimens
暂无分享,去创建一个
A. Antinori | L. Minoli | C. Torti | E. Quiros-Roldan | F. Maggiolo | D. Ripamonti | F. Suter | P. Nasta | C. Arici | L. Sighinolfi
[1] P. Harrigan,et al. Adherence–resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness , 2006, AIDS.
[2] Steve A Castillo,et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] M. Wainberg,et al. Resistance Issues With New Nucleoside/Nucleotide Backbone Options , 2004, Journal of acquired immune deficiency syndromes.
[4] W. Heneine,et al. Transmitted Human Immunodeficiency Virus Type 1 Carrying the D67N or K219Q/E Mutation Evolves Rapidly to Zidovudine Resistance In Vitro and Shows a High Replicative Fitness in the Presence of Zidovudine , 2004, Journal of Virology.
[5] V. Johnson,et al. Rate of Thymidine Analogue Resistance Mutation Accumulation With Zidovudine- or Stavudine-Based Regimens , 2004, Journal of acquired immune deficiency syndromes.
[6] O. Kirk,et al. Clinical trial methodology and clinical cohorts: the importance of complete follow-up in trials evaluating the virological efficacy of anti-HIV medicines , 2004, Current opinion in infectious diseases.
[7] V. Calvez,et al. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure , 2004, Journal of medical virology.
[8] Gene D Morse,et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. , 2003, The New England journal of medicine.
[9] Victoria A Johnson,et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] F. Brun-Vézinet,et al. Predictive Factors and Selection of Thymidine Analogue Mutations by Nucleoside Reverse Transcriptase Inhibitors According to Initial Regimen Received , 2003, Antiviral therapy.
[11] Andrea De Luca,et al. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. , 2002, AIDS research and human retroviruses.
[12] G. Beall,et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. , 2002, The New England journal of medicine.
[13] Robert W. Shafer,et al. Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance , 2002, Clinical Microbiology Reviews.
[14] Joseph Quinn,et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults , 2001, AIDS.
[15] K. Squires,et al. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I) , 2000, AIDS.
[16] R. Harrigan,et al. Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies , 2000, AIDS.
[17] B. Clotet,et al. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial , 2000, AIDS.
[18] B. Larder,et al. Mutational Patterns in the HIV Genome and Cross-Resistance following Nucleoside and Nucleotide Analogue Drug Exposure , 2000, Antiviral therapy.
[19] K. Tashima,et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. , 1999, The New England journal of medicine.
[20] P. Tebas,et al. Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir. , 1999, AIDS.
[21] D. Kuritzkes,et al. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients , 1996, AIDS.